- Home
- IAS vs AGIO Comparison
IAS vs AGIO Comparison
Compare IAS & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAS
- AGIO
- Stock Information
- Founded
- IAS 2009
- AGIO 2007
- Country
- IAS United States
- AGIO United States
- Employees
- IAS N/A
- AGIO N/A
- Industry
- IAS Computer Software: Programming Data Processing
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- IAS Technology
- AGIO Health Care
- Exchange
- IAS Nasdaq
- AGIO Nasdaq
- Market Cap
- IAS 1.7B
- AGIO 2.0B
- IPO Year
- IAS 2021
- AGIO 2013
- Fundamental
- Price
- IAS $10.37
- AGIO $35.22
- Analyst Decision
- IAS Buy
- AGIO Buy
- Analyst Count
- IAS 11
- AGIO 7
- Target Price
- IAS $14.80
- AGIO $56.33
- AVG Volume (30 Days)
- IAS 734.6K
- AGIO 621.1K
- Earning Date
- IAS 02-28-2025
- AGIO 02-13-2025
- Dividend Yield
- IAS N/A
- AGIO N/A
- EPS Growth
- IAS 258.32
- AGIO N/A
- EPS
- IAS 0.20
- AGIO 11.64
- Revenue
- IAS $511,358,000.00
- AGIO $36,498,000.00
- Revenue This Year
- IAS $11.95
- AGIO $166.22
- Revenue Next Year
- IAS $11.91
- AGIO $98.36
- P/E Ratio
- IAS $52.81
- AGIO $3.03
- Revenue Growth
- IAS 11.77
- AGIO 36.07
- 52 Week Low
- IAS $7.98
- AGIO $27.14
- 52 Week High
- IAS $17.53
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- IAS 45.61
- AGIO 54.02
- Support Level
- IAS $10.29
- AGIO $33.25
- Resistance Level
- IAS $10.98
- AGIO $34.86
- Average True Range (ATR)
- IAS 0.31
- AGIO 1.33
- MACD
- IAS -0.03
- AGIO 0.37
- Stochastic Oscillator
- IAS 16.89
- AGIO 97.99
About IAS Integral Ad Science Holding Corp.
Integral Ad Science Holding Corp is a digital advertising verification company. The cloud-based technology platform of the company delivers independent measurement and verification of digital advertising across all devices, channels, and formats, including desktop, mobile, connected TV, social, display, and video. Geographically, the company derives a majority of its revenue from the Americas region.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.